Mesothelioma Cancer Malignant neoplasms
Conditions
Interventions
Three Arms:
1. Active symptom control (ASC) only
2. ASC and mitomycin (8 mg/m^2), vinblastine (6 mg/m^2) and cisplatin (50 mg/m^2) every 21 days for four cycles
Sponsors
Medical Research Council (MRC) (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Microscopically and immunohistochemically confirmed malignant mesothelioma including epithelial and other histological types 2. Any symptomatic pleural effusion treated and brought under control before trial entry 3. Computed tomography (CT) scan to be performed within a month prior to randomisation 4. Patients who have undergone surgical resection of mesothelioma are eligible provided two CT scans, six weeks apart show stable or progressive disease 5. No previous chemotherapy for mesothelioma 6. No other disease or previous malignancy 7. World Health Organization (WHO) performance status zero to two 8. Medically fit to receive chemotherapy 9. Quality of life (QOL) forms completed 10. Signed informed consent
Exclusion criteria
Exclusion criteria: Not provided at time of registration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The outcome measures were: 1. The acceptability of the study design to patients 2. Suitability of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and EORTC Lung Cancer 13-item module (LC13) and Functional Assessment of Cancer Therapy - Lung (FACT-L) QOL questionnaires for mesothelioma 3. Palliation | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcome measures | — |
Countries
England, United Kingdom
Outcome results
None listed